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ABSTRACT 
Adipogenesis is the process by which mesenchymal stem cells (MSCs) develop into lipid-
laden adipocytes. Being the dominant cell type within adipose tissue, adipocytes play a 
central role in regulating circulating fatty acid levels, which is considered to be of critical 
importance in maintaining insulin sensitivity. High temperature requirement protease A1 
(HTRA1) is a newly recognized regulator of MSC differentiation, although its role as a 
mediator of adipogenesis has not yet been defined. The aim of this work was therefore to 
evaluate HTRA1’s influence on human MSC (hMSC) adipogenesis and to establish a 
potential mode of action. We report that the addition of exogenous HTRA1 to human 
hMSCs undergoing adipogenesis suppressed their ability to develop into lipid laden 
adipocytes. These effects were demonstrated as being reliant on both its protease and PDZ 
domain, and were mediated through the actions of c-Jun N-terminal kinase (JNK) and 
matrix metalloproteinases (MMPs). The relevance of such findings with regards to 
HTRA1’s potential influence on adipocyte function in vivo, is made evident by the fact that 
HTRA1 and MMP-13 were readily identifiable within crown-like structures present in 
visceral adipose tissue samples from insulin resistant obese human subjects. These data 
therefore implicate HTRA1 as a negative regulator of MSC adipogenesis and are 
suggestive of its potential involvement in adipose tissue remodeling under pathological 
conditions. 
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INTRODUCTION 
Multipotent mesenchymal stem cells (MSCs) represent an important source of adipocytes, 
undergoing adipogenesis in two phases consisting of commitment to pre-adipocytes and 
their terminal differentiation into mature adipocytes [1, 2]. Of critical importance in the 
body’s ability to adapt to energy requirements, is the capacity for pre-adipocytes to 
develop into adipocytes and for them to be able to acquire more fat. Both these conditions 
require alterations in cell shape and volume, and are heavily reliant on the versatility and 
integrity of the adipocyte extracellular matrix (ECM), termed basal lamina [3]. The basal 
lamina is composed of numerous core proteins, including type IV collagen [4, 5], various 
laminin isoforms [5], and heparan sulfate proteoglycan (HSPG) [6] to name but a few, and 
is subject to continual turnover mediated by a wide variety of matrix metalloproteinases 
(MMPs) [7, 8]. Interference with basal lamina dynamics may therefore have significant 
consequences to adipogenesis and subsequent adipocyte stability. 
Dysregulation of adipogenesis and adipose tissue remodeling has been linked to 
several human disorders, most notably of which is obesity-induced insulin resistance [9, 
10]. A characteristic feature of obese adipose tissue is the presence of crown-like structures 
consisting mainly of infiltrating macrophages surrounding dead adipocytes [11]. Exposure 
to such an environment not only impairs adipocyte responsiveness to insulin, but can also 
lead to deviations in the differentiation status of pre-adipocytes [9]. As such, there is 
currently a strong focus on the identification of key factors involved in the regulation of 
adipogenic commitment. 
High temperature requirement protease A1 (HTRA1) has been newly identified as a 
modulator of human MSC (hMSC) differentiation, whereby it acts to enhance osteoblast 
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formation most likely through proteolytic modification of the ECM, and its expression 
levels in bone tissue coincide with the appearance of new bone formation during fracture 
repair in mice [12]. Furthermore, preliminary findings from loss of function studies have 
suggested that HTRA1’s ability to influence hMSC lineage commitment may extend to 
adipogenic differentiation [12]. However, the extent to which these effects are mediated by 
secreted HTRA1 and the possible mechanisms underlining its mode of action remain to be 
determined. Certainly, the growing number of reports pertaining to HTRA1’s ability to 
modulate the ECM both under normal physiological conditions and in disease, may 
provide some basis for how it could potentially interact with and regulate adipocyte 
formation [13-15].  
To define HTRA1’s role in adipogenesis and its potential physiological relevance, 
we investigated the effects of exogenously added recombinant HTRA1 on the development 
of hMSCs into mature adipocytes and further analysed its expression levels in visceral 
adipose tissue from obese patients. We demonstrate that HTRA1 acts to significantly 
suppress adipocyte development, primarily through upregulation of JNK activity and MMP 
production. We further localized HTRA1 and MMP-13 to sites of crown-like structures 
within the adipose tissue of an insulin resistant obese patient. This work thus identifies 
HTRA1 as being a potentially novel mediator of adipose tissue homeostasis.   
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MATERIALS AND METHODS 
 
Materials 
Anti-ERK1/2, anti-phospho-ERK1/2 (Thr202/Tyr204), anti-SAPK/JNK, anti-phospho-
SAPK/JNK (Thr183/Tyr185), anti-p38, anti-phospho-p38 (Thr180/Tyr182) were all 
purchased from Cell signaling Technology (Leiden, The Netherlands). Anti-tubulin was 
from Sigma-Aldrich. Anti-type IV collagen (M3F7) and anti-laminin γ-1 (2E8) were from 
the Developmental Studies Hybridoma Bank (University of Iowa). Anti-fibronectin 
(MAB1936) was from Merck Millipore (Schaffhausen, Switzerland). Monoclonal anti-
human HTRA1 was generously supplied by Prof. Michael Ehrmann (University Duisburg-
Essen, Germany) and generated as previously described [16].  Rabbit anti-MMP-13 was 
purchased from Abcam (Cambridge, UK). Mouse IgG, HRP- or Cy3-labeled secondary 
antibodies specific for mouse or rabbit IgG were purchased from Jackson 
ImmunoResearch (Suffolk, UK), and biotin-labeled goat anti-mouse IgG and Vectastain 
ABC system used in immunohistochemical staining studies was from Reactolab SA 
(Servion, Switzerland). Biotinylated swine anti-rabbit IgG was from Dako (Baar, 
Switzerland). Histidine-labeled human HTRA1 proteins were overexpressed in E. coli and 
purified using previously described methodologies [16].  
 
hMSC Culture 
The hMSCs employed in this work were provided by the Texas A&M Health Science 
Center College of Medicine Institute for Regenerative Medicine at Scott & White through 
a grant from NCRR of the NIH, Grant # P40RR017447. hMSCs were isolated from bone 
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marrow aspirates and multipotency fully defined  in accordance with the minimal criteria 
outlined by International Society for Cellular Therapy [17]. hMSCs were maintained at 
37°C, in 5% CO2 and 98% humidity in normal growth medium consisting of Dulbecco’s 
modified eagle medium (DMEM-low glucose, with GlutaMAX) (Life Technologies, Zug, 
Switzerland), supplemented with 10% fetal bovine serum (FBS, BioWest), 
penicillin/streptomycin (50 units/ml; 50 µg/ml), and used between passage 5 and 8 unless 
otherwise stated.  
 
Adipogenic differentiation of hMSCs 
The adipogenic differentiation of hMSCs was performed using a protocol previously 
established in our laboratory [12]. Briefly, hMSCs seeded in cell culture plates at 10’000 
cells/cm
2
 were incubated for 3 days with adipogenic induction medium consisting of 
normal growth medium (DMEM-high glucose, GlutaMAX) supplemented with 1 µM 
dexamethasone, 10 µg/ml insulin, 0.1 mM Indomethacin, and 0.5 mM 
isobutylmethylxanthine (IBMX) (all from Sigma-Aldrich). Cells were subsequently 
cultured in adipogenic maintenance medium consisting of IBMX-free adipogenic medium, 
and replenished with fresh medium every 72 h for up to 14-24 days unless otherwise stated. 
Adipocyte formation was confirmed by positive staining of lipid droplets by Oil Red O 
(Sigma-Aldrich). Oil Red O staining was quantified by extraction with isopropanol 
absorption measured at 510 nm using a Multiplate reader (Infinite M200, Tecan). Values 
were normalized to cell number assessed by DAPI staining as described below. For 
recombinant HTRA1 addition studies, hMSCs undergoing adipogenesis were treated with 
recombinant HTRA1 starting at day 3 after adipogenic induction. Dose response 
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experiments determined 45 nM to be the most appropriate concentration of HTRA1 to use 
for these studies (Supporting Information Fig. S1A). For inhibition studies, cells were 
treated with recombinant HTRA1 in the presence of MMP-3 inhibitor NNGH, MMP-13 
inhibitor CL-82198, or MAP Kinase inhibitors PD98059, SP600125 and SB239063 (all 
from Enzo Life Science, Lausen, Switzerland). DMSO (0.05%) was added as vehicle 
control and was equivalent to highest concentration of inhibitor used.  
 
RT-qPCR 
Gene expression levels were quantified by reverse-transcription quantitative PCR (RT-
qPCR) using TaqMan Gene Expression Assays (Life Technologies) (Supporting 
Information Table S1) as previously described [12]. Total RNA was harvested from cells 
at selected time points during differentiation and 0.5µg of total RNA reverse-transcribed 
using Superscript II (Life Technologies). An equivalent of 10ng total RNA was applied as 
cDNA template in the successive qRT-PCR reaction using the StepOnePlus (Life 
Technologies). Values were normalized to GUSB mRNA levels and presented as fold 
change as compared to control cells or cells treated with vehicle alone (value = 1) 
according to the 2
-∆∆CT
 method. 
 
siRNA Assays 
Silencing of HTRA1 and MMP13 gene expression was performed with Silencer Select 
siRNA oligos (Life Technologies) according to the manufacturer’s protocol as previously 
described [12]. For HTRA1 knockdown, hMSCs (1 x10
5
) were transfected with 40 nM 
HTRA1-specific (s11279, s11280) or negative control siRNA (Negative Control-1) using 
Page 8 of 68
 9 
the NEON Transfection System (Life Technologies). Transfected cells were immediately 
seeded in cell culture plates with fresh growth medium (without antibiotics) and incubated 
for 24 h at 37°C, 5% CO2. Medium was then replaced with either fresh growth medium or 
adipogenic differentiation and total RNA and supernatants harvested at selected time 
points for further analysis. For MMP13 knockdown, adherent hMSCs were initially seeded 
in cell culture plates and cultured in induction medium for 3 days. Thereafter, hMSCs were 
transfected for 24 h with 40 nM MMP13-specific (11496, 104024) or negative control 
siRNA (Negative Control-1) using Lipofectamine RNAiMAX (Life Technologies). 
Supernatants were subsequently replaced with adipogenic maintenance medium and total 
RNA and supernatants harvested at selected time points for further analysis. The effect of 
HTRA1 and MMP13 gene silencing on lipid droplet formation was evaluated by Oil Red O 
staining as described above.  
 
Proteolysis Assays 
HTRA1 mediated digestion of BODIPY-FL-labeled DQ-elastin or DQ-type IV collagen 
was performed using EnzChek assay kits (Life Technologies) as previously described [18]. 
 
ELISAs 
Extracellular protein levels of HTRA1, MMP-3, MMP-13, syndecan-1 and -4 were 
measured in the supernatants of hMSCs at selected time points by ELISA. The HTRA1 
ELISA was performed as previously described [19]. The MMP-3, MMP-13, Syndecan-1 
and -4 specific ELISAs were performed using Duo-Set ELISA Development Systems 
according to the manufacturer's instructions (R & D Systems, Abingdon, UK). 
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FACS Analysis 
Subconfluent adherent hMSCs were detached using Accutase (Life Technologies) and 
resuspended in ice cold FACS buffer (PBS/BSA 0.1%) in round bottom 96-well plates to 2 
x10
6
/ml. Cells were incubated on ice for 1 h with equimolar concentrations of his-labeled 
recombinant HTRA1 either alone, or in combination with heparin, heparanase, 
chondroitinase (all from Sigma-Aldrich), collagenase (Roche), or peptide competitors of 
integrin binding CS1 and GRGDSP (from ANAWA Trading SA, Zurich, Switzerland). 
Cells were then washed in cold FACS buffer and incubated with a FITC conjugated rabbit 
anti-6xHis tag antibody (Lucerna-Chem, Luzern, Switzerland) on ice for 1 h. Bound 
HTRA1 was detected by FACS analysis using a FACS-Canto II (BD Biosciences) and 
quantified using FlowJo 10 software.  
 
Protein Electrophoresis and Immunoblotting 
Whole cell extracts from untreated or HTRA1 treated hMSCs were harvested using 
CelLytic
 
M (Sigma Aldrich) supplemented with protease and phosphatase inhibitor 
cocktails (Sigma Aldrich) and 1mM PMSF at 2 weeks post adipogenic induction. Protein 
concentrations were determined by Bradford-based protein assay (Bio-Rad). Protein 
samples were boiled for 5 min in loading buffer (50 mM Tris-HCl, pH 6.8, 2% (v/v) SDS, 
10% (v/v) glycerol, 100 mM DTT, 0.002% (w/v) bromophenol blue) and equal amounts of 
protein analyzed by SDS-PAGE using or 10% or 4-15% precast Tris-HCl gels (BioRad) 
under reducing conditions and electroblotted onto PVDF membranes using the Trans-Blot 
Turbo blotting system (BioRad). Membranes were then blocked with 5% (w/v) skim milk 
Page 10 of 68
 11
in TBST (50mM Tris-HCl, pH 7.6, 150mM NaCl, 0.05% (v/v) Tween 20) for 1 h at room 
temperature and then incubated with specific antibodies overnight at 4°C at recommended 
dilutions in blocking buffer. Antibody binding was detected using HRP-conjugated 
secondary antibodies followed by incubation in Super Signal West Pico or West Dura 
Chemiluminescent Substrate (Life Technologies) and exposed to x-ray film. 
 
Preparation and identification of Fnfs 
For the identification of native Fnfs in supernatants, hMSCs undergoing adipogenic 
differentiation for 14 days were treated for a further 24 h with HTRA1 (45 nM) in fresh 
growth medium without FCS. Where indicated, HTRA1 was also added in combination 
with CL-82198 (20 nM). Supernatants were then harvested and immediately placed on ice. 
Cellular debris was removed by centrifugation and the remaining supernatant concentrated 
40-fold by centrifugation at 3000G for 30 min in Amicon Ultra columns (10 kDa size 
exclusion, Millipore). Concentrated protein solutions were then supplemented with 
protease inhibitor cocktail (1:100, Sigma Aldrich) and 1mM PMSF and separated on a 4-
15% SDS-PAGE pre-cast gel (BioRad). Methods for preparing purified Fnfs generated 
from HTRA1-digested plasma fibronectin were carried out as previously described [18]. 
Fnfs were visualized by immunoblotting using a specific antibody against the N-terminus 
of fibronectin and detected using an HRP-conjugated secondary antibody as described 
above.  
 
VLDL uptake 
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Lipid uptake by hMSCs undergoing adipogenesis was performed using DiI-labeled human 
VLDL (KALEN Biomedical) at late time points of adipogenesis between days 18-24. 
Cultured hMSCs were rinsed once with PBS and then incubated for 3 h under standard 
culture conditions in assay buffer supplemented with DiI-labeled VLDL (4 µg/ml) and 
carrier protein ApoE2 (3 µg/ml, PeproTech, UK). Following incubation, cells were washed 
3 times with PBS and fixed with PBS-buffered formaldehyde (4%) for 30 min. Nuclei 
were stained with DAPI (1:10’000) in PBS for 10 min and mounted in Mowiol containing 
2.5% (w/v) DABCO. Images were captured using a Leica DMI6000B automated inverted 
research microscope system (Leica Microsystems). Relative mean fluorescence intensity 
(RMFI) was quantified using NIH ImageJ software as described previously with some 
modifications [20]. Briefly, images were processed using identical image acquisition 
settings and exposure times. TIFF files were converted to 8-bit gray-scale mode and 
inverted onto a white background. Negative and positive staining controls were used to set 
measurable limits and threshold levels, and were then applied to all samples. Finally, 
RMFI was calculated as mean grey value per area and normalized to the number of cells 
per image as assessed by automated counting of DAPI-positive nuclei staining using the 
ImageJ software.   
 
Immunofluorescence staining 
hMSCs undergoing adipogenesis were fixed with PBS-buffered formaldehyde (4%) for 30 
min, washed 3 times with PBS and then blocked for 30 min in 2% BSA and 5% normal 
goat serum in PBS. Cells were incubated overnight at 4
o
C with a monoclonal mouse anti-
type IV collagen or monoclonal mouse anti-Laminin γ-1 antibodies, or an isotype control 
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at an equivalent concentration. Antibody binding was detected using a Cy3-conjugated 
secondary antibody and nuclei stained with DAPI. Cells were mounted with Mowiol 
containing 2.5% DABCO and images captured using a Leica DMI6000B automated 
inverted research microscope system (Leica Microsystems). Positive staining was 
quantified as described above. RMFI was quantified using NIH ImageJ software as 
described above. 
 
Immunohistochemical staining 
Dewaxed paraffin sections of adipose tissue were rehydrated and blocked in normal serum 
(Jackson ImmunoResearch) for 30 min. Sections were then incubated for 1 h at 37
o
C with 
monoclonal mouse anti-HTRA1 (2.5 µg/ml) or rabbit anti-MMP-13 (5 µg/ml) and staining 
specificity controlled for using either mouse or rabbit IgG at equivalent concentrations. 
Sections were then washed in PBS and incubated with biotinylated goat anti-mouse IgG 
(1:200) or swine anti-rabbit IgG (1:400) for 1 h at 37
o
C followed by washing and a further 
incubation for 30 min with Vectastain. Sections were then developed using 3,3' 
diaminobenzidine tetrahydrochloride (DAB), counterstained with Harris’ Hematoxylin and 
mounted in Mowiol. 
 
Human Patients 
Visceral tissue was obtained during bariatric surgery from morbidly obese, non-diabetic 
patients (Supporting Information Table S2). All adipose tissue donors gave written 
informed consent before the study, which had been approved by the Ethics Committee of 
the Medical Faculty, University of Leipzig. Insulin sensitivity was defined by the glucose 
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infusion rate (GIR) during the steady state of an euglycemic hyperinsulinemic clamp as 
previously described [21]. 
 
Statistical Analysis 
Two-tailed unpaired Student’s t-test for comparison of two groups or one-way analysis of 
variance (ANOVA) with Tukey’s post hoc test for multiple group comparisons were used. 
In all cases, a P-value of < 0.05 was considered statistically significant, and all data were 
expressed as mean ± standard deviation (S.D). 
 
RESULTS 
 
HTRA1 suppresses lipid uptake and droplet formation in hMSCs undergoing 
adipogenesis 
Preliminary studies utilizing an HTRA1-specific ELISA were conducted to investigate 
HTRA1 production by hMSCs. In undifferentiated control hMSCs, secreted HTRA1 levels 
increased over culture time, reaching a maximum level of 9.6 ± 0.5 ng/ml after 10 days of 
culture (Fig. 1A). HTRA1 production also increased over time in hMSC cultures 
undergoing adipogenesis, although levels were significantly reduced as compared to the 
undifferentiated control hMSCs throughout the 2 week culture period. Interestingly, these 
observations are in direct contrast to the stimulatory effects of osteogenic induction on 
HTRA1 production by hMSCs (Supporting Information Fig. S1B) [12]. These data 
therefore suggest that reductions in HTRA1 might be involved in adipogenic 
differentiation of hMSCs. To address this model, we effectively eliminated endogenous 
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HTRA1 from the culture system through the use of small interfering RNA (siRNA) 
(Supporting Information Fig. S1C) and assessed the ability of hMSCs to undergo 
adipogenesis using Oil Red O staining. Indeed, hMSCs deficient in HTRA1 produced 
significantly more lipid droplets than those treated with control siRNA, thereby indicating 
that loss of HTRA1 had an overall positive influence on adipocyte formation (Fig. 1B). 
Furthermore, stimulation of HTRA1 deficient hMSCs with functional HTRA1 could 
reduce Oil Red O staining to a level comparable to that observed in control cultures (Fig. 
1C). These studies also provided the first evidence that the addition of exogenous HTRA1 
acts to suppress lipid droplet formation in developing adipocytes. Note that an HTRA1 
variant (∆Mac) was used that is lacking its N-terminal Mac domain, for which no function 
is known to date [22] (Supporting Information Fig. S1D). Furthermore, N-terminal 
truncation does not affect HTRA1 function (Supporting Information Fig. S1E) and 
therefore this variant is termed HTRA1 throughout. 
As HTRA1 contains both a C-terminal PDZ domain and a functional serine 
protease domain, we asked whether either domain was required for determining HTRA1’s 
inhibitory influence over hMSC adipogenesis. Therefore, we generated several different 
proteolytically active and inactive recombinant HTRA1 proteins (Supporting Information 
Fig. S1D and S1E) and assessed their ability to influence oil droplet formation in hMSCs 
undergoing adipogenesis. Indeed, inactivation of HTRA1’s proteolytic activity through 
replacement of residue Ser328 with Ala (HTRA1 S328A), significantly impaired it’s 
ability to inhibit lipid droplet formation in hMSCs undergoing adipogenesis (Fig. 1D). 
Similarly, deletion of the PDZ domain in proteolytically active HTRA1 (HTRA1∆PDZ) 
also abolished its inhibitory action on hMSC adipogenesis. Molecular based analyses 
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revealed HTRA1 treatment had no significant influence on the expression levels of 
adipogenic-associated markers PPARG, FABP4 and CD36, and only a minimal, but 
significant inhibitory effect on the expression level of the adipocyte-specific marker 
ADIPOQ (1.3-fold; p < 0.01) (Supporting Information Fig. S2). Therefore, HTRA1’s 
capacity to regulate adipogenic gene expression was not considered to be sufficient to 
account for its inhibitory actions on oil droplet formation in hMSCs undergoing adipogenic 
differentiation. When considering alternative routes through which HTRA1 could 
modulate hMSC adipogenesis, we became aware of a previous study in which HTRA1 was 
shown to cleave Xenopus syndecan-4 [23]. Syndecans are cell surface HSPGs and 
represent a predominant feature of developing adipocytes, in which they play a central role 
in mediating lipid uptake [6]. In order to investigate this, we assessed the potential for 
various recombinant HTRA1 proteins to bind to hMSCs using fluorescence activated cell 
sorting (FACS) analysis. We could demonstrate that intact, but proteolytically inactive 
HTRA1 S328A was able to bind to hMSCs in a PDZ-dependent manner (Fig. 2A). The 
involvement of the PDZ domain in cellular binding of HTRA1 was further substantiated 
through the use of a recombinant HTRA1 containing the PDZ domain only 
(HTRA1∆protease) (Fig. 2B). We next investigated whether removal of heparan sulfate 
(HS) using heparanase or competition with heparin could reduce cellular binding of 
HTRA1, and thereby provide support for an HTRA1-HSPG interaction. Indeed, the ability 
of HTRA1 S328A (Fig. 2C) and HTRA1∆protease (Fig. 2D) to bind to hMSCs was 
markedly reduced by pre-treatment with heparanase. Similarly, pre-treatment of cells with 
heparin could also dramatically reduce cellular binding of both HTRA1 S328A (Fig. 2E) 
and HTRA1∆protease (Fig. 2F). By contrast, replacement of heparanase with collagenase 
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(Supporting Information Fig. S3A) or chondroitinase (Supporting Information Fig. S3B), 
and heparin with integrin-binding competitor peptides CS-1 (Supporting Information Fig. 
S3C) or GRGDSP (Supporting Information Fig. S3D), had little or no effect on the cellular 
binding capacity of HTRA1’s PDZ domain. 
Although these data demonstrated HTRA1’s ability to bind to HSPG, they fell short 
of confirming whether HSPG was a proteolytic substrate of HTRA1. To address this 
question, we used an ELISA to determine levels of cleaved soluble syndecan-4 in 
supernatants from hMSCs at various stages of adipogenesis. Low levels of soluble 
syndecan-4 were observed at day 10 (4.2 pg/ml ± 1.5) and day 21 (16.4 pg/ml ± 1.9) in 
hMSCs undergoing adipogenesis (Fig. 2G). By contrast, significantly higher soluble 
syndecan-4 levels were measured in hMSCs treated with HTRA1 at day 10 (44.8 pg/ml ± 
3.5; P < 0.001) and day 21 (84 pg/ml ± 7.7; P < 0.001). Again, these effects were 
determined as being dependent on HTRA1 possessing an intact PDZ domain, and were 
therefore in accordance with the findings from our binding studies. Studies were also 
undertaken to examine soluble syndecan-1. However, protein levels remained below 
detection limits in all treatment groups (data not shown). Based on syndecan-4 being a 
prominent regulator of lipid uptake by differentiating adipocytes [6], we surmised that 
HTRA1-induced syndecan-4 shedding would result in  significant impairment of this 
process. Studies to investigate active lipid uptake in hMSCs undergoing adipogenesis were 
therefore undertaken using fluorescently labeled VLDL (VLDL-DiI). The uptake and 
accrual of high levels of VLDL-DiI in normally differentiating cells was apparent after a 3 
h incubation period (Fig. 2H). However, VLDL-DiI levels were significantly diminished in 
hMSCs that had previously been treated with HTRA1. Furthermore, the inability of 
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HTRA1 to exert a significant influence over VLDL-DiI uptake in the absence of either a 
protease or PDZ domain, convincingly supports a causal relationship between HTRA1’s 
ability to impair lipid accrual in hMSCs undergoing adipogenesis and its propensity to 
interact with and cleave HSPG from the cell surface.  
 
Induction of MMPs by HTRA1 
Although HTRA1 has the potential to directly interact with and cleave HSPG, it is also 
possible that the observed effects are indirect e.g. via other proteases. Our previous studies 
utilizing synovial fibroblasts and intervertebral disc cells have identified MMPs to be 
strongly upregulated in response to HTRA1 stimulation, being mediated through the 
production of reactive fibronectin species [18, 19]. In addition to their ability to induce 
HSPG cleavage and shedding [24], MMPs are also potent regulators of adipogenesis, 
having both inhibitory and stimulatory effects [7, 8, 25]. This led us to investigate the 
possibility that MMP production by hMSCs undergoing adipogenesis might be regulated 
by HTRA1. Indeed, treatment of hMSCs undergoing adipogenesis with HTRA1 resulted in 
significant increases in the mRNA expression levels of MMP1 (Fig. 3A), MMP2 (Fig. 3B), 
MMP3 (Fig. 3C), MMP9 (Fig. 3D), and MMP13 (Fig. 3E), although no significant 
alterations were observed in MMP14 expression levels (Fig. 3F). Additionally, ELISA 
measurements of supernatants revealed significant increases in MMP-3 (Fig. 3G) and 
MMP-13 (Fig. 3H)  protein levels. Small, but significant increases in MMP9 and MMP13 
mRNA expression, along with MMP-3 and -13 protein production, were also observed in 
hMSCs treated with HTRA1 S328A, although to a significantly lesser degree as compared 
to HTRA1. In order to ascertain whether the observed increases in MMP production were 
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associated with increases in MMP activity, we undertook immunofluorescence studies to 
assess the levels of major MMP substrates present within cultures of differentiating 
hMSCs. The basal lamina of hMSCs undergoing adipogenesis stained positive for both 
laminin (Fig. 4A) and type IV collagen (Fig. 4B) at day 22 after adipogenic induction. 
Based on HTRA1’s ability to upregulate MMP production, we additionally examined 
whether it could also induce alterations in type IV collagen and laminin in hMSC cultures 
undergoing adipogenesis. Indeed, treatment with HTRA1 resulted in a significant 
reduction in the levels of both laminin (Fig. 4A) and type IV collagen (Fig. 4B). 
Furthermore, the effects of HTRA1 were significantly more pronounced than either 
HTRA1 S328A or HTRA1∆PDZ, and were therefore in accordance with HTRA1’s ability 
to regulate MMP production. Although it’s possible that changes in the basal lamina were 
additionally due to factors other than MMPs, we are confident that they were not the direct 
result of HTRA1’s actions based on the findings from previous studies in which HTRA1 
failed to degrade either type IV collagen or laminin [13]. Indeed, we were only able to 
observe partial degradation of type IV collagen by HTRA1 at concentrations starting from 
0.86 µM, 20-fold higher than that used in our culture system (Supporting Information Fig. 
S4). 
As HTRA1-generated fibronectin fragments (Fnfs) are known to be potent 
stimulators of MMP production [18, 19], we additionally investigated whether such 
fragments could be identified within hMSCs undergoing adipogenesis. Protein analysis of 
supernatants from hMSCs identified several Fnf species, including the well described 29 
kDa Fnf (Supporting Information Fig. S5A) [18, 19]. Interestingly, levels of this particular 
fragment decreased upon adipogenic induction of control cultures, but was still present in 
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the supernatants of HTRA1-treated hMSC cultures undergoing adipogenesis. Furthermore, 
proteolytic inactive HTRA1 S328A failed to generate elevated levels of Fnfs, thereby 
confirming it to be dependent on HTRA1’s protease activity. In order to investigate 
whether the 29 kDa Fnf had the same capabilities as HTRA1 in terms of stimulating MMP 
production by hMSCs undergoing adipogenesis, we purified HTRA1-generated Fnfs 
(Supporting Information Fig. S5B) and assessed their ability to influence MMP expression 
in comparison to HTRA1. Although Fnfs at a final concentration of up to 40 µg/ml were 
able to stimulate MMP1 (Supporting Information Fig. S5C), MMP3 (Supporting 
Information Fig. S5D) and MMP13 (Supporting Information Fig. S5E) expression in 
hMSCs undergoing adipogenesis, levels were significantly reduced as compared to 
HTRA1 treatment. Moreover, the addition of Fnfs failed to have any significant impact on 
the level of oil droplet formation in hMSCs undergoing adipogenesis (Supporting 
Information Fig. S5F). It therefore seems unlikely than Fnfs are the major instigators of 
MMP production and adipogenic suppression in hMSCs in response to HTRA1 addition.  
 
The inhibitory effects of HTRA1 are dependent on MMP and MAP kinase activation 
Having established MMP overproduction as being a predominant feature in HTRA1 
stimulated hMSCs, we sought to determine whether they had any significant relevance in 
defining HTRA1’s influence over hMSC adipogenesis. In order to investigate this, we 
utilized MMP inhibitors NNGH and CL-82198 at concentrations deemed to be selective 
for the inhibition of MMP-3 and MMP-13 respectively [26, 27], as well as siRNA targeted 
knockdown of MMP13 gene expression. Initial immunofluorescence studies confirmed 
that type IV collagen levels were significantly elevated in HTRA1-treated cultures when 
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exposed to NNGH (Fig. 5A) or CL-82198 (Fig. 5B) as compared to hMSCs treated with 
HTRA1 alone. Similarly, both NNGH (Fig. 5C) and CL-82198 (Fig. 5D) significantly 
reduced HTRA1’s ability to generate cleaved soluble syndecan-4 in hMSC cultures 
undergoing adipogenesis in a concentration dependent manner. Based on our assumption 
that alterations in basal lamina composition are the predominant driving force behind 
HTRA1’s anti-adipogenic effects, we anticipated that the inhibition of either MMP-3 or 
MMP-13 in HTRA1-treated cultures should preserve adipocyte development as compared 
to hMSCs treated with HTRA1 alone. In order to investigate this, we quantified Oil Red O 
staining in HTRA1-treated hMSCs undergoing adipogenesis cultured in the presence or 
absence of either MMP inhibitor. Our findings confirmed that inhibition of either MMP-3 
(Fig. 5E) or MMP-13 (Fig. 5F) could significantly restore oil droplet formation in HTRA1-
treated hMSCs undergoing adipogenesis to levels similar to those observed in 
differentiating hMSCs cultured in the absence of HTRA1. These observations were 
additionally supported by studies in which MMP13 gene expression was silenced in 
hMSCs undergoing adipogenesis. MMP13 expression could be effectively suppressed in 
both HTRA1-treated and untreated hMSCs undergoing adipogenesis (Supporting 
Information Fig. S6A), and was shown to significantly impair HTRA1’s ability to inhibit 
oil droplet formation as determined by quantitative analysis of Oil Red O staining 
(Supporting Information Fig. S6B). Furthermore, when analyzing the supernatants of 
HTRA1-treated hMSCs undergoing adipogenesis in which the MMP-13 inhibitor had been 
added, we observed a clear decrease in the amount of the HTRA1-generated 29 kDa Fnf 
(Supporting Information Fig. S6C and S6D). This finding therefore lends additional 
support to the theory that in this culture system at least, HTRA1’s capacity to induce MMP 
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expression and impair adipogenesis in hMSCs is primarily mediated through mechanisms 
unrelated to Fnfs, and that at least in the case of MMP-13, Fnf generation in cultured 
hMSCs is actually dependent on the actions of MMPs rather than HTRA1 proteolysis 
directly.  
 Having therefore confirmed the central importance of MMPs in mediating 
HTRA1’s effects on hMSC adipogenesis, we explored potential mechanisms through 
which HTRA1 could induce MMP production. Our previous findings from studies utilizing 
primary cultures of IVD cells have hinted towards the MAP kinase signaling pathway as 
playing a significant role in mediating the upregulation of MMPs in response to HTRA1 
[18]. Moreover, alterations in MAP kinase activation are known to have a profound 
influence on both adipogenesis and adipose tissue function [28]. Based on this, we 
investigated the role of MAP kinase signaling in adipogenesis and evaluated its 
involvement in mediating HTRA1’s effects on hMSC adipogenesis. Initial Western blot 
analysis of hMSCs undergoing adipogenesis revealed minimal levels of activated ERK, 
JNK and p38 at day 14 post induction (Fig. 6A). By contrast, phosphorylated levels of both 
ERK, JNK and p38 were noticeably increased in HTRA1-treated hMSCs in both a protease 
and PDZ dependent manner. In order to further investigate the involvement of MAP kinase 
signaling in MMP expression in hMSCs undergoing adipogenesis, we utilized MAP kinase 
inhibitors PD98059, SP600125 and SB239063 at concentrations deemed to be selective for 
the inhibition of ERK, JNK and p38 respectively [29, 30]. Treatment of hMSCs 
undergoing adipogenesis with MAP kinase inhibitors significantly reduced the basal 
expression of MMP3 at day 17 post induction (Fig. 6B). The enhanced MMP3 expression 
observed in HTRA1-treated hMSCs undergoing adipogenesis was similarly reduced 
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following the addition of MAP kinase inhibitors. By contrast, no significant changes in 
MMP13 expression levels were observed in hMSCs undergoing adipogenesis treated with 
PD98059, and HTRA1’s ability to upregulate MMP13 expression was not significantly 
affected (Fig. 6C). However, inhibition of JNK or p38 activity had a profound effect on 
both basal MMP13 levels, as well as on HTRA1-mediated upregulation of MMP13 
expression. In order to assess the possible consequence of such changes in MMP 
expression on hMSC adipogenesis, we investigated the effects of MAP kinase inhibitors on 
oil droplet formation in hMSCs undergoing adipogenesis. Neither PD98059 or SP600125 
had any significant effect on oil droplet formation in normally differentiating hMSCs (Fig. 
6D). By contrast, basal levels of oil droplet formation were dramatically reduced in control 
cultures treated with SB239063. The addition of either PD98059 or SP600125 to HTRA1-
treated hMSCs undergoing adipogenesis resulted in significant increases in Oil Red O 
staining, and in the case of SP600125, fully restored oil droplet formation to levels 
comparable to those observed in cultures undergoing adipogenesis in the absence of 
HTRA1. However, the addition of SB239063 failed to alleviate the inhibitory effects of 
HTRA1, and instead led to a significant reduction in Oil Red O staining as compared to 
hMSCs treated with HTRA1 alone. 
 
Detection of HTRA1 in visceral fat from obese patients 
In order to validate the relevance of these findings with regards to HTRA1’s potential role 
in mediating adipogenesis in vivo, immunohistochemical analysis was performed on 
visceral adipose tissue taken from obese patients (Supporting Information Table S2) that 
were diagnosed as being either insulin sensitive (IS) or insulin resistant (IR) as described 
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previously in detail [21]. Analysis of visceral fat from either IS (Supporting Information 
Fig. S7A) or IR (Supporting Information Fig. S7B) obese patients revealed HTRA1 
primarily localized to large blood vessels found throughout the tissue. HTRA1 was also 
identified in areas of crown-like structures in both IS (Fig. 7A) and IR (Fig. 7B) 
(Supporting Information Fig. S8) obese patients although the level of staining at these sites 
was markedly enhanced in IR adipose tissue in accordance with increases in cellular 
content. Furthermore, HTRA1 positive crown-like structures also showed positive staining 
for MMP-13 (Fig. 7C), thus re-enforcing the concept of there being a close working 
relationship between these two proteases. In all cases, specificity of immunostaining was 
confirmed using relevant IgG isotype controls (Fig. 7D-F).  
 
DISCUSSION 
In the current study, we have identified HTRA1 as a potent inducer of MAP kinase-
dependent MMP production in hMSC cultures undergoing adipogenesis, the result of 
which leads to modulation of ECM components and impaired lipid droplet accrual in 
differentiating cells. Furthermore, the observation that HTRA1 is present at high levels in 
visceral adipose tissue in crown-like structures is suggestive of its active involvement in 
mediating adipose tissue function under pathological conditions. 
 HTRA1 is now well established as a key regulator of ECM turnover, having been 
linked to various diseases in which the breakdown of normal ECM is a prominent 
pathological feature [13-16, 18]. Findings from our own studies into the role of HTRA1 in 
joint and IVD degeneration have led to the suggestion that HTRA1 may instigate tissue 
breakdown through an upregulation in MMP production, most likely via the action of 
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reactive Fnf species [18, 19]. In the context of adipose tissue, MMP-mediated ECM 
remodelling and reorganization forms an integral part of normal tissue homeostasis, being 
required for adipocyte differentiation and function [7, 8]. Abnormal fluctuations in MMP 
levels within adipose tissue may therefore represent an important factor in determining 
adipocyte health and subsequent risk of disease. This is supported by our current findings 
where increased production of MMPs by hMSCs undergoing adipogenesis in response to 
HTRA1 led to a loss of vital ECM components and impaired lipid accrual. Such 
observations are therefore suggestive of HTRA1 as having a detrimental role in hMSC 
adipogenesis and that these effects are related to the actions of MMPs, in particular MMP-
3 and MMP-13. However, it should be noted that all studies in the current report were 
performed using two dimensional culture systems, and may have therefore overlooked the 
potential involvement of other MMPs, such as MMP-14, whose regulatory role in 
adipogenesis is only made apparent when examined under three dimensional culture 
systems [31]. Furthermore, in contrast to previous studies [18, 19], the effects of HTRA1 
do not appear to be reliant on the generation of Fnfs. In fact, we provide evidence to 
suggest that MMP-13 itself may be responsible for the appearance of such fragments in 
response to HTRA1. As such, alternative mechanisms must exist through which HTRA1 
can instigate changes in hMSC MMP production and adipogenic potential.  
Some insights into HTRA1’s mode of action could be gleaned through 
manipulation of its trypsin-like serine protease domain and its protein-binding PDZ 
domain. Certainly, both domains were of critical importance in determining HTRA1’s 
inhibitory influence over hMSC adipogenesis, being required for both efficient MMP 
production as well as for the observed decreases in type IV collagen, laminin and lipid 
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uptake in hMSCs undergoing adipogenesis. Of particular interest was the novel finding 
that HTRA1 could interact with surface bound HS in a PDZ-dependent manner. It is 
possible therefore that sequestration of HTRA1 to the cell surface by HS would allow for 
close interactions to form between HTRA1 and HS-containing glycoproteins. This concept 
is supported by the finding that increased levels of soluble syndecan-4 could be detected in 
in the supernatants of differentiating hMSC cultures treated with structurally intact HTRA1. 
Syndecans are important regulators of lipid uptake in differentiating adipocytes [6, 32] and 
their liberation from the cell surface by proteolytic cleavage may constitute a potential 
cause of diminished lipid accrual in hMSCs undergoing adipogenesis following HTRA1 
treatment. In addition to syndecans, numerous other glycoproteins also exist within the 
adipocyte ECM, including the previously identified HTRA1 substrate nidogen [13]. 
Nidogen represents an important stabilizing component of the adipocyte basal lamina 
through its binding to type IV collagen and laminin [33]. The possible targeting of nidogen 
by HTRA1 may therefore represent an alternative means through which the ECM could be 
affected by HTRA1, and adipogenesis inhibited. Interestingly, nidogen cleavage by 
HTRA1 also has the potential to generate various fragment species in vitro, although their 
influence on MMP production and adipogenesis remains to be determined.  
HTRA1’s ability to both induce MMP production and inhibit hMSC adipogenesis 
was additionally identified as being dependent on the activities of JNK, and to a lesser 
extent, ERK. Interpretation of the data concerning the involvement of p38 were hampered 
by the fact that inhibition of p38 activation resulted in a significant reduction in oil droplet 
formation in hMSCs undergoing adipogenesis regardless of treatment conditions. The 
regulation of MMP expression by MAP kinases is well documented [reviewed in 34], and 
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several studies have now identified ERK and JNK as potent negative regulators of MSC 
adipogenesis [35-37]. Despite having demonstrated the importance of MAP kinase 
activation in mediating the effects of HTRA1 during hMSC adipogenesis, we were unable 
to ascertain the cause for such signaling events. Certainly, both the proteolytic activity and 
PDZ domain of HTRA1 were essential requirements for efficient MAP kinase activation, 
thereby inferring substrate binding and degradation were necessary. One potential means 
by which HTRA1 could invoke MAP kinase activation in the context of the current study, 
is through syndecan-4 shedding, whereby disruption of the syndecan-4 to MAP kinase 
signaling cascade may have contributed to increases in JNK activity levels [38].  
The relevance of such findings is made apparent by the fact that both MAP kinases 
and MMPs are centrally linked to the pathophysiology of adipose tissue, being implicated 
in the development of insulin resistance in obese mice and humans [28, 39, 40]. Adipocyte 
dysfunction clearly plays a major role in determining the severity of insulin resistance 
among obese patients and as such, factors which negatively influence adipocyte 
development are likely to contribute to and potentially exacerbate  the disease state [9]. In 
this regard, inappropriately high levels of HTRA1 in the adipose tissue of obese 
individuals may be viewed as being potentially harmful and an indication of deficiencies in 
adipocyte development and function. The significance of this is made evident by the fact 
that HTRA1 could be detected in the visceral fat from a small cohort of obese patients, and 
that levels were greatest at sites where crown-like structures were most apparent. This, 
together with the fact that MMP-13 was also localized to these same regions, lends further 
support to the concept of HTRA1 representing a novel mediator of adipogenesis and fat 
turnover.  
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CONCLUSIONS 
In conclusion, our findings identify high levels of exogenous HTRA1 as having a negative 
influence of hMSC adipogenesis in vitro, being mediated through activation of MAP 
kinase signaling and subsequent increases in MMP production. Furthermore, elevated 
levels of HTRA1 and MMP-13 proteins were evident in crown-like structures in visceral 
adipose tissue samples of insulin-resistant obese patients. Such observations may therefore 
be of relevance when considering HTRA1’s potential role in the underlying processes 
governing adipose tissue and adipocyte dysregulation.  
 
ACKNOWLEDGEMENTS 
SG and GB were supported by SNSF grants 31003A_134935 and 31003A_156313. AM 
and NAT were supported by the Uniscientia Foundation and the Forschungskredit 
University of Zurich.. The authors would like to express their gratitude to Daniela Kern for 
preparing the patient tissue sections. 
 
DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST 
The authors indicate no potential conflicts of interest. 
 
REFERENCES 
1. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev 
Mol Cell Biol 2006;7:885–896. 
Page 28 of 68
 29
2. Christodoulides C, Lagathu C, Sethi JK et al. Adipogenesis and WNT signalling. 
Trends Endocrinol Metab 2009;20:16-24. 
3. Mariman EC, Wang P. Adipocyte extracellular matrix composition, dynamics and role 
in obesity. Cell Mol Life Sci 2010;67:1277-92.  
4. Sillat T, Saat R, Pöllänen R et al. Basement membrane collagen type IV expression by 
human mesenchymal stem cells during adipogenic differentiation. J Cell Mol Med 
2012;16:1485-95.  
5. Noro A, Sillat T, Virtanen I et al. Laminin production and basement membrane 
deposition by mesenchymal stem cells upon adipogenic differentiation. J Histochem 
Cytochem 2013;61:719-30.  
6. Wilsie LC, Chanchani S, Navaratna D et al. Cell surface heparan sulfate proteoglycans 
contribute to intracellular lipid accumulation in adipocytes. Lipids Health Dis 2005;4:2. 
7. Maquoi E, Munaut C, Colige A et al. Modulation of adipose tissue expression of 
murine matrix metalloproteinases and their tissue inhibitors with obesity. Diabetes 
2002;51:1093-101. 
8. Chavey C, Mari B, Monthouel MN et al. Matrix metalloproteinases are differentially 
expressed in adipose tissue during obesity and modulate adipocyte differentiation. J 
Biol Chem 2003;278:11888-96.  
9. Guilherme A, Virbasius JV, Puri V et al. Adipocyte dysfunctions linking obesity to 
insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008;9:367-77.  
10. Lee MJ, Wu Y, Fried SK. Adipose tissue remodeling in pathophysiology of obesity. 
Curr Opin Clin Nutr Metab Care 2010;13:371-6.  
Page 29 of 68
 30
11. Cinti S, Mitchell G, Barbatelli G et al. Adipocyte death defines macrophage 
localization and function in adipose tissue of obese mice and humans. J Lipid Res 
2005;46:2347-55.  
12. Tiaden AN, Breiden M, Mirsaidi A et al. Human serine protease HTRA1 positively 
regulates osteogenesis of human bone marrow-derived mesenchymal stem cells and 
mineralization of differentiating bone-forming cells through the modulation of 
extracellular matrix protein. Stem Cells 2013;30:2271-2282. 
13. Vierkotten S, Muether PS, Fauser S. Overexpression of HTRA1 leads to ultrastructural 
changes in the elastic layer of Bruch's membrane via cleavage of extracellular matrix 
components. PLoS One 2011;6:e22959.  
14. Tiaden AN, Richards PJ. The emerging roles of HTRA1 in musculoskeletal disease. 
Am J Pathol 2013;182:1482–1488. 
15. Beaufort N, Scharrer E, Kremmer E et al. Cerebral small vessel disease-related 
protease HtrA1 processes latent TGF-β binding protein 1 and facilitates TGF-β 
signaling. Proc Natl Acad Sci U S A 2014;111:16496-501.  
16. Grau S, Baldi A, Bussani R et al. Implications of the serine protease HtrA1 in amyloid 
precursor protein processing. Proc Natl Acad Sci U S A 2005;102:6021-6. 
17. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent 
mesenchymal stromal cells. The International Society for Cellular Therapy position 
statement. Cytotherapy 2006;8:315-7. 
18. Tiaden AN, Klawitter M, Lux V et al. Detrimental role for human high temperature 
requirement serine protease A1 (HTRA1) in the pathogenesis of intervertebral disc 
(IVD) degeneration. J Biol Chem 2012;287:21335-45.  
Page 30 of 68
 31
19. Grau S, Richards PJ, Kerr B et al. The role of human HtrA1 in arthritic disease. J Biol 
Chem 2006;281:6124-9.  
20. Burgess A, Vigneron S, Brioudes E et al. A Loss of human Greatwall results in G2 
arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A 
balance. Proc Natl Acad Sci U S A 2010;107:12564-9.  
21. Klöting N, Fasshauer M, Dietrich A et al. Insulin-sensitive obesity. Am J Physiol 
Endocrinol Metab 2010;299:E506-15. 
22. Eigenbrot C, Ultsch M, Lipari MT et al. Structural and functional analysis of HtrA1 
and its subdomains. Structure 2012;20:1040-50. 
23. Hou S, Maccarana M, Min TH et al.The secreted serine protease xHtrA1 stimulates 
long-range FGF signaling in the early Xenopus embryo. Dev Cell 2007;13:226-41. 
24. Manon-Jensen T, Multhaupt HA, Couchman JR. Mapping of matrix metalloproteinase 
cleavage sites on syndecan-1 and syndecan-4 ectodomains. FEBS J 2013;280:2320-31.  
25. Shih CL, Ajuwon KM. Inhibition of MMP-13 prevents diet-induced obesity in mice 
and suppresses adipogenesis in 3T3-L1 preadipocytes. Mol Biol Rep 2015;42:1225-32.  
26. Kim EM, Shin EJ, Choi JH et al. Matrix metalloproteinase-3 is increased and 
participates in neuronal apoptotic signaling downstream of caspase-12 during 
endoplasmic reticulum stress. J Biol Chem 2010;285:16444-52.  
27. Rath T, Stöckle J, Roderfeld M et al. Matrix metalloproteinase-13 is regulated by toll-
like receptor-9 in colorectal cancer cells and mediates cellular migration. Oncol Lett 
2011:2:483-488.  
28. Bost F, Aouadi M, Caron L et al. The role of MAPKs in adipocyte differentiation and 
obesity. Biochimie 2005;87:51-6.  
Page 31 of 68
 32
29. Ando C, Takahashi N, Hirai S et al. Luteolin, a food-derived flavonoid, suppresses 
adipocyte-dependent activation of macrophages by inhibiting JNK activation. FEBS 
Lett 2009:583:3649-54. 
30. Vallet S, Mukherjee S, Vaghela N et al. Activin A promotes multiple myeloma-
induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad 
Sci U S A 2010;107:5124-9. 
31. Chun TH, Hotary KB, Sabeh F, Saltiel AR, Allen ED, Weiss SJ. A pericellular 
collagenase directs the 3-dimensional development of white adipose tissue. Cell 
2006;125:577-91. 
32. Kasza I, Suh Y, Wollny D et al. Syndecan-1 is required to maintain intradermal fat and 
prevent cold stress. PLoS Genet 2014;10:e1004514.  
33. Yurchenco PD. Basement membranes: cell scaffoldings and signaling platforms. Cold 
Spring Harb Perspect Biol 2011;3:a004911. 
34. Reuben PM, Cheung HS. Regulation of matrix metalloproteinase (MMP) gene 
expression by protein kinases. Front Biosci 2006;11:1199-215. 
35. Tominaga S, Yamaguchi T, Takahashi S et al. Negative regulation of adipogenesis 
from human mesenchymal stem cells by Jun N-terminal kinase. Biochem Biophys Res 
Commun 2005;326:499-504. 
36. Chiu LH, Yeh TS, Huang HM et al. Diverse effects of type II collagen on osteogenic 
and adipogenic differentiation of mesenchymal stem cells. J Cell Physiol 
2012;227:2412-20.  
Page 32 of 68
 33
37. Fu L, Tang T, Miao Y et al. Stimulation of osteogenic differentiation and inhibition of 
adipogenic differentiation in bone marrow stromal cells by alendronate via ERK and 
JNK activation. Bone 2008;43:40-7.  
38. Saoncella S, Calautti E, Neveu W et al. Syndecan-4 regulates ATF-2 transcriptional 
activity in a Rac1-dependent manner. J Biol Chem 2004;279:47172-6.  
39. Unoki H, Bujo H, Shibasaki M et al. Increased matrix metalloproteinase-3 mRNA 
expression in visceral fat in mice implanted with cultured preadipocytes. Biochem 
Biophys Res Commun 2006;350:392-8. 
40. Meissburger B, Ukropec J, Roeder E et al. Adipogenesis and insulin sensitivity in 
obesity are regulated by retinoid-related orphan receptor gamma. EMBO Mol Med 
2011;3:637-51.  
 
Page 33 of 68
 34
Figure 1.  HTRA1 suppresses lipid uptake and droplet formation in hMSCs undergoing 
adipogenesis. (A): hMSCs were incubated in growth medium (control) or adipogenic 
induction medium (adipogenic) for up to 14 days and secreted HTRA1 protein levels 
determined by ELISA. *p < 0.001 as compared to hMSCs undergoing adipogenesis. (B): 
hMSCs were treated with scrambled siRNA (scr) or siRNAs specific for HTRA1 (H1 and 
H2) and induced to undergo adipogenesis. On day 14 following adipogenic induction, cells 
were stained using Oil Red O and oil droplet accrual quantified and normalized to cell 
number. Scale bar = 1 mm. (C): hMSCs were treated with siRNA specific for HTRA1 
(H2), HTRA1 (45 nM) or a combination of both H2 and HTRA1 and induced to undergo 
adipogenesis. On day 14 following adipogenic induction, cells were stained using Oil Red 
O and oil droplet accrual quantified and normalized to cell number. *p < 0.01 as compared 
to siRNA (scr) treated cells. (D): hMSCs were induced to undergo adipogenesis in the 
absence (untreated) or presence of 45 nM of recombinant wild type HTRA1 (HTRA1), 
proteolytic inactive HTRA1 (HTRA1 S328A) or proteolytic active HTRA1 without PDZ 
domain (HTRA1∆PDZ). On day 14 following adipogenic induction, cells were stained 
using Oil Red O and oil droplet accrual quantified and normalized to cell number. *p < 
0.001 as compared to untreated. Scale bar = 1 mm. Data are representative of at least 2 
separate experiments performed in triplicate. Abbreviations: hMSC, human mesenchymal 
stem cells; ELISA, enzyme-linked immunosorbent assay; HTRA1, high temperature 
requirement protease A1; siRNA, small interfering RNA. 
 
Figure 2. HTRA1 interacts with surface bound HSPG. (A-F): hMSC were incubated with 
recombinant his-labeled HTRA1 protein (0.45 µM) on ice for 1 h, washed and HTRA1 
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binding determined by FACS analysis using a FITC labeled anti-histidine antibody. hMSC 
binding of PDZ domain-containing HTRA1 S328A (A) or HTRA1∆protease (B) as 
compared to HTRA1∆PDZ. In order to investigate the involvement of HSPG in the 
binding of recombinant HTRA1 protein, cells were pre-treated with heparanase (10 U/ml) 
or  heparin (10 µg/ml). hMSC binding of S328A (C, E) and HTRA1∆protease (D, F) in the 
presence of heparanase (C, D) or heparin (E, F). (G): hMSCs were induced to undergo 
adipogenesis in the absence (untreated) or presence of 45 nM of recombinant wild type 
HTRA1 (HTRA1), proteolytic inactive HTRA1 (HTRA1 S328A) or proteolytic active 
HTRA1 without PDZ domain (HTRA1∆PDZ). ELISA measurements of soluble syndecan-
4 were performed at day 10 and 21 post adipogenic induction. (H): hMSCs were induced 
to undergo adipogenesis in the absence (untreated) or presence of 45 nM of recombinant 
wild type HTRA1 (HTRA1), proteolytic inactive HTRA1 (HTRA1 S328A) or proteolytic 
active HTRA1 without PDZ domain (HTRA1∆PDZ). At day 24 post adipogenic induction, 
hMSCs were rinsed once with PBS and incubated for an additional 3 h with DiI-labeled 
VLDL and carrier protein ApoE2. VLDL-DiI (red) uptake was quantified by measuring 
relative linear median fluorescence intensity (RMFI) using NIH ImageJ software and 
normalized to cell number. Nuclei were stained with DAPI (blue). Scale bar = 75 µm. *p < 
0.001 as compared to untreated hMSCs. Data are representative of at least 2 separate 
experiments performed in triplicate. Abbreviations: hMSC, human mesenchymal stem 
cells; HTRA1, high temperature requirement protease A1; HSPG, heparan sulfate 
proteoglycan; ELISA, enzyme-linked immunosorbent assay; FITC, Fluorescein 
isothiocyanate; VLDL-DiI, very low density lipoprotein-dialkylcarbocyanine. 
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Figure 3. HTRA1 upregulates MMP production by hMSCs undergoing adipogenesis. 
hMSCs were induced to undergo adipogenesis in the absence (untreated) or presence of 45 
nM of recombinant wild type HTRA1 (HTRA1), proteolytic inactive HTRA1 (HTRA1 
S328A) or proteolytic active HTRA1 without PDZ domain (HTRA1∆PDZ). At 21 days 
post adipogenic induction, expression levels of MMP1 (A), MMP2 (B), MMP3 (C), MMP9 
(D), MMP13 (E) and MMP14 (F) were determined by RT-qPCR. Data was normalized to 
GUSB and expressed as fold change as compared to untreated hMSCs (value = 1) using the 
comparative CT method. (G, H): hMSCs were induced to undergo adipogenesis in the 
absence (untreated) or presence of 45 nM of recombinant wild type HTRA1 (HTRA1), 
proteolytic inactive HTRA1 (HTRA1 S328A) or proteolytic active HTRA1 without PDZ 
domain (HTRA1∆PDZ). At 21 days post adipogenic induction, levels of secreted MMP-3 
(G) and -13 (H) were determined in hMSC supernatants using specific ELISAs. *p < 0.05, 
**p < 0.001 as compared to untreated hMSCs. Data are representative of at least 2 separate 
experiments performed in triplicate. Abbreviations: hMSC, human mesenchymal stem 
cells; HTRA1, high temperature requirement protease A1; MMP, matrix 
metalloproteinase; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; 
ELISA, enzyme-linked immunosorbent assay. 
 
Figure 4. Immunofluorescence analysis of ECM. hMSCs were induced to undergo 
adipogenesis in the absence (untreated) or presence of 45 nM of recombinant wild type 
HTRA1 (HTRA1), proteolytic inactive HTRA1 (HTRA1 S328A) or proteolytic active 
HTRA1 without PDZ domain (HTRA1∆PDZ). At day 24 post adipogenic induction, 
hMSCs were stained with antibodies specific for laminin (A) or type IV collagen (B) and 
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positive staining detected using a Cy3-labelled secondary antibody (red). 
Immunofluorescence was quantified by measuring relative linear median fluorescence 
intensity (RMFI) using NIH ImageJ software and normalized to cell number. Nuclei were 
stained with DAPI (blue). Scale bar = 100 µm. *p < 0.01 as compared to untreated hMSCs. 
Data is representative of at least 2 separate experiments performed in triplicate. 
Abbreviations: hMSC, human mesenchymal stem cells; HTRA1, high temperature 
requirement protease A1. 
 
Figure 5. HTRA1’s effects are mediated through MMP activities. (A, B): hMSCs 
pretreated with either vehicle control or with 10 µM of NNGH (A) or 20 µM of CL-82198 
(B) were induced to undergo adipogenesis in the absence (untreated) or presence of 45 nM 
of recombinant wild type HTRA1 (HTRA1). At day 22 post adipogenic induction, hMSCs 
were stained with an antibody against type IV collagen and positive staining detected using 
a Cy3-labelled secondary antibody. Immunofluorescence was quantified by measuring 
relative linear median fluorescence intensity (RMFI) using NIH ImageJ software and 
normalized to cell number. (C, D): hMSCs pretreated with either vehicle control or with 
varying concentrations of NNGH (C) or CL-82198 (D) were induced to undergo 
adipogenesis in the absence (untreated) or presence of 45 nM of recombinant wild type 
HTRA1 (HTRA1). At day 17 post adipogenic induction, soluble syndecan-4 levels were 
measured in supernatants by specific ELISA. (E, F): hMSCs pretreated with either vehicle 
control or with varying concentrations of NNGH (E) or CL-82198 (F) were induced to 
undergo adipogenesis in the absence (untreated) or presence of 45 nM of recombinant wild 
type HTRA1 (HTRA1). At day 18 post adipogenic induction, cells were stained using Oil 
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Red O and oil droplet accrual quantified and normalized to cell number. *p < 0.05, **p < 
0.01, ***p < 0.001 as compared to controls from untreated or HTRA1-treated groups 
respectively. Data are representative of at least 2 separate experiments performed in 
triplicate. Abbreviations: hMSC, human mesenchymal stem cells; HTRA1, high 
temperature requirement protease A1; MMP, matrix metalloproteinase; ELISA, enzyme-
linked immunosorbent assay. 
 
Figure 6. HTRA1’s effects are mediated through MAP kinase activities. (A): hMSCs were 
induced to undergo adipogenesis in the absence (untreated) or presence of 45 nM of 
recombinant wild type HTRA1 (HTRA1), proteolytic inactive HTRA1 (HTRA1 S328A) or 
proteolytic active HTRA1 without PDZ domain (HTRA1∆PDZ). At day 14 post 
adipogenic induction, protein lysates were subjected to Western blot analysis using 
antibodies specific for phosphorylated and non-phosphorylated JNK, p38 and ERK. An 
anti-tubulin monoclonal was used to confirm equal loading. (B-D): hMSCs pretreated with 
either vehicle control or with PD98059 (10 µM), SP600125 (20 µM) or SB239063 (10 
µM) were induced to undergo adipogenesis in the absence (untreated) or presence of 45 
nM of recombinant wild type HTRA1 (HTRA1). At day 17 post adipogenic induction, 
expression levels of MMP3 (B) and MMP13 (C) were determined by RT-qPCR. Data was 
normalized to GUSB and expressed as fold change relative to untreated, control hMSCs 
(value = 1) using the comparative CT method. (D): Oil Red O staining was also performed 
and oil droplet accrual quantified and normalized to cell number.  *p < 0.05, **p < 0.01, 
***p < 0.001 as compared to controls from untreated or HTRA1-treated groups 
respectively. Data are representative of at least 2 separate experiments performed in 
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triplicate. Abbreviations: hMSC, human mesenchymal stem cells; HTRA1, high 
temperature requirement protease A1; MMP, matrix metalloproteinase; MAP, mitogen-
activated protein; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; 
GUSB, Glucuronidase beta. 
 
Figure 7. Identification of HTRA1 in adipose tissue. Paraffin wax sections of human 
visceral (omental) adipose tissue from insulin sensitive (IS) or insulin resistant (IR) obese 
patients were incubated with an anti-HTRA1 antibody (A, B), anti-MMP-13 antibody (C) 
or relevant IgG controls (D-F), and positive staining identified using an appropriate HRP-
labeled polyclonal antibody with subsequent development using 3,3'-diaminobenzidine 
(brown). Arrow heads, HTRA1 or MMP-13 present in crown-like structures. Scale bar = 
200 µm. Abbreviations: HTRA1, high temperature requirement protease A1; MMP, matrix 
metalloproteinase; HRP, horseradish peroxidase. 
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Supplementary Fig. 1. (A): hMSCs were induced to undergo adipogenesis in the presence 
of varying concentrations of recombinant wild type HTRA1 (HTRA1) ranging from 0 to 
45 nM, and its influence on oil droplet accrual determined by Oil Red O staining. *p < 
0.01 as compared hMSCs cultured in the absence of HTRA1. (B): hMSCs were incubated 
in growth medium (control), osteogenic induction medium (osteogenic) or adipogenic 
induction medium (adipogenic) for up to 14 days and endogenous HTRA1 protein levels 
measured in supernatants by specific ELISA. *p < 0.001 as compared hMSCs cultured in 
growth medium at the equivalent time points. (C): hMSCs were treated with scrambled 
siRNA (scr) or siRNAs specific for HTRA1 (H1 and H2) and induced to undergo 
adipogenesis. Endogenous levels of HTRA1 were measured in supernatants at day 3 post 
adipogenic induction using a specific ELISA. *p < 0.001 as compared to scrambled siRNA 
(scr) treated cells. (D): Schematic of recombinant human HTRA1 proteins; active HTRA1 
(∆Mac), inactive HTRA1 (HTRA1 S328A), active HTRA1 without PDZ domain 
(HTRA1∆PDZ), inactive HTRA1 without PDZ domain (HTRA1 S328A∆PDZ) and 
HTRA1 without protease domain (HTRA1∆protease). The purified recombinant histidine-
labeled human HTRA1 proteins were also visualized on a Coomassie blue-stained SDS-
PAGE gel. M, protein marker; lane 1, HTRA1; lane 2, HTRA1 S328A; lane 3, 
HTRA1∆PDZ; lane 4, HTRA1 S328A∆PDZ; lane 5, HTRA1∆protease. (E): Proteolytic 
activity of recombinant HTRA1 proteins (45 nM) towards BODIPY-FL-labeled DQ elastin 
(25 µg/ml) at 37
o
C as determined using a Multiplate reader. Abbreviations: hMSC, human 
mesenchymal stem cells; HTRA1, high temperature requirement protease A1; ELISA, 
enzyme-linked immunosorbent assay; siRNA, small interfering RNA; SDS-PAGE, sodium 
dodecyl sulfate polyacrylamide gel electrophoresis. 
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Supplementary Fig. 2. Influence of HTRA1 on adipogenic markers. hMSCs were induced 
to undergo adipogenesis in the absence (untreated) or presence of 45 nM of recombinant 
wild type HTRA1 (HTRA1), proteolytic inactive HTRA1 (HTRA1 S328A) or proteolytic 
active HTRA1 without PDZ domain (HTRA1∆PDZ). At 21 days post adipogenic 
induction, expression levels of PPARG (A), FABP4 (B), CD36 (C) and ADIPOQ (D) were 
determined by RT-qPCR. Data was normalized to GUSB and expressed as fold change as 
compared to untreated hMSCs (value = 1) using the comparative CT method. *p < 0.01 as 
compared to untreated cells. Abbreviations: hMSC, human mesenchymal stem cells; 
HTRA1, high temperature requirement protease A1; PPARG, peroxisome proliferator-
activated receptor gamma; FABP4, fatty acid binding protein 4; CD36, cluster of 
differentiation 36; ADIPOQ, adiponectin; GUSB, Glucuronidase beta; RT-qPCR, reverse 
transcription-quantitative polymerase chain reaction. 
 
Supplementary Fig. 3. FACS analysis of recombinant HTRA1 binding to non-
differentiated hMSCs. HTRA1∆protease (0.45 µM) was incubated with hMSCs for 1 h at 
4
o
C and cell-bound HTRA1 protein detected using a FITC labeled anti-his antibody. The 
influence of pre-incubating cells with collagenase (1 mg/ml) (A), chondroitinase (10 U/ml) 
(B), CS1 (50 µM) (C) or GRGDSP (50 µM) (D) on the percentage of cell-bound 
HTRA1∆protease was calculated using FlowJo 10 software. Data are representative of 
least two individual experiments performed in duplicate. Abbreviations: hMSC, human 
mesenchymal stem cells; HTRA1, high temperature requirement protease A1; FACS, 
fluorescence activated cells sorting. 
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Supplementary Fig. 4. Capacity for HTRA1 to degrade type IV collagen. Varying 
concentrations of HTRA1 or HTRA1 S328A were incubated with DQ-type IV collagen 
(25 µg/ml) at 37
o
C and the relative fluorescence units (RFU) generated after 24 h 
determined using a Multiplate reader. Abbreviations: HTRA1, high temperature 
requirement protease A1. 
 
Supplementary Fig. 5. (A): Western blot analysis of native Fnfs in concentrated 
supernatants harvested from 14 day old undifferentiated hMSCs (control), untreated 
hMSCs undergoing adipogenesis, or hMSCs undergoing adipogenesis treated with 45 nM 
of wild type HTRA1 or proteolytic inactive HTRA1 (HTRA1 S328A) for a further 24 h. 
Protein was subjected to immunoblotting using antibody Mab 1936 specific for the 
fibronectin amino-terminal fibrin- and heparin-binding domain. Arrow head indicates the 
HTRA1-cleaved 29 kDa Fnf. (B): An equimolar ratio of human plasma-derived Fn and 
wild type HTRA1 were incubated in TBS, pH 8.5, for 16 h at 37
o
C and Fnfs purified by 
affinity chromatography and analysed on a Coomassie Blue stained 4-15% gradient SDS-
PAGE gel. Fn and HTRA1 alone were also loaded and served as controls. Arrow head 
indicates the purified 29 kDa Fnf due to HTRA1-mediated cleavage. (C-E): hMSCs were 
induced to undergo adipogenesis in the absence (untreated) or presence of 45 nM of 
recombinant wild type HTRA1 (HTRA1), purified HTRA1-digested Fn (40 µg/ml) 
(Fn+HTRA1) or TBS, pH 7.6, eluate from the affinity purification reaction using HTRA1 
alone (TBS+HTRA1). At 11 days post adipogenic induction, expression levels of MMP1 
(C), MMP3 (D) and MMP13 (E) were determined by RT-qPCR. Data was normalized to 
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GUSB and expressed as fold change as compared to untreated hMSCs (value = 1) using the 
comparative CT method. (F): hMSCs were induced to undergo adipogenesis in the absence 
(untreated) or presence of 45 nM of recombinant wild type HTRA1 (HTRA1), Fn+HTRA1 
or TBS+HTRA1. At day 14 following adipogenic induction, cells were stained using Oil 
Red O and oil droplet accrual quantified and normalized to cell number. *p < 0.05, **p < 
0.01, ***p < 0.001 as compared to untreated cells. Scale bar = 2 mm. Data are 
representative of least two individual experiments performed in triplicate. Abbreviations: 
hMSC, human mesenchymal stem cells; HTRA1, high temperature requirement protease 
A1; Fnf, fibronectin fragments; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel 
electrophoresis; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; 
GUSB, Glucuronidase beta; MMP, matrix metalloproteinase; TBS, Tris-buffered saline. 
 
Supplementary Fig. 6. (A): hMSCs pre-treated with scrambled control siRNA (scr) or 
siRNAs specific for MMP13 (M1 and M2) were induced to undergo adipogenesis in the 
absence (untreated) or presence of 45 nM wild type HTRA1 (HTRA1). At day 3 post 
adipogenic induction, MMP13 gene expression was determined by RT-qPCR. Data was 
normalized to GUSB and expressed as fold change relative to siRNA (scr) controls from 
untreated hMSCs (value = 1) using the comparative CT method. (B): hMSCs pre-treated 
with scrambled control siRNA (scr) or siRNAs specific for MMP13 (M1 and M2) were 
induced to undergo adipogenesis in the absence (untreated) or presence of 45 nM wild type 
HTRA1 (HTRA1). At day 22 post adipogenic induction, cells were stained using Oil Red 
O and oil droplet accrual quantified and normalized to cell number. (C): hMSCs were 
induced to undergo adipogenesis for 14 days and then treated for 24 h without (untreated) 
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or with CL-82198 (20 µM), HTRA1 (45 nM) or HTRA1 and CL-82198. Cell supernatants 
were harvested, concentrated and subjected to Western blot analysis using an antibody 
specific for the amino-terminal fibrin- and heparin-binding domain of fibronectin. *p < 
0.05, **p < 0.01, ***p < 0.001 as compared to siRNA (scr) controls from untreated or 
HTRA1-treated groups respectively. Data are representative of least two individual 
experiments performed in triplicate. Arrow heads indicate the 29 kDa Fnf due to HTRA1 
treatment. (D): Coomassie stained gel of total protein from supernatants to control for 
equal loading. Data are representative of least two individual experiments. Abbreviations: 
hMSC, human mesenchymal stem cells; HTRA1, high temperature requirement protease 
A1; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; GUSB, 
Glucuronidase beta; MMP, matrix metalloproteinase; siRNA, small interfering RNA; Fnf, 
fibronectin fragments. 
 
Supplementary Fig. 7. Identification of HTRA1 in adipose tissue. Paraffin wax sections 
of human visceral (omental) adipose tissue from IS or IR obese patients were incubated 
with an anti-HTRA1 antibody (A, B) or relevant IgG controls (C, D), and positive staining 
identified using an appropriate HRP-labeled polyclonal antibody with subsequent 
development using 3,3'-diaminobenzidine (brown). Asterisks, HTRA1-positive blood 
vessels. Scale bar = 200 µm. Insulin sensitivity was defined as glucose infusion rate (GIR) 
during the steady state of an euglycemic-hyperinsulinemic clamp > 70 µmol/kg/min, 
insulin resistance as GIR < 50 µmol/kg/min. Abbreviations: HTRA1, high temperature 
requirement protease A1; IS, insulin sensitive; IR, insulin resistant; HRP, horseradish 
peroxidase. 
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Supplementary Fig. 8. High power image of HTRA1 in human visceral (omental) adipose 
tissue from obese patient 4 (IR). Paraffin sections were incubated with an anti-HTRA1 
antibody and positive staining identified using an appropriate HRP-labeled polyclonal 
antibody with subsequent development using 3,3'-diaminobenzidine (brown). Scale bar = 
20 µm. Abbreviations: HTRA1, high temperature requirement protease A1; IR, insulin 
resistant; HRP, horseradish peroxidase. 
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Figure 1. HTRA1 suppresses lipid uptake and droplet formation in hMSCs undergoing adipogenesis. (A): 
hMSCs were incubated in growth medium (control) or adipogenic induction medium (adipogenic) for up to 
14 days and secreted HTRA1 protein levels determined by ELISA. *p < 0.001 as compared to hMSCs 
undergoing adipogenesis. (B): hMSCs were treated with scrambled siRNA (scr) or siRNAs specific for HTRA1 
(H1 and H2) and induced to undergo adipogenesis. On day 14 following adipogenic induction, cells were 
stained using Oil Red O and oil droplet accrual quantified and normalized to cell number. Scale bar = 1 mm. 
(C): hMSCs were treated with siRNA specific for HTRA1 (H2), HTRA1 (45 nM) or a combination of both H2 
and HTRA1 and induced to undergo adipogenesis. On day 14 following adipogenic induction, cells were 
stained using Oil Red O and oil droplet accrual quantified and normalized to cell number. *p  < 0.01 as 
compared to siRNA (scr) treated cells. (D): hMSCs were induced to undergo adipogenesis in the absence 
(untreated) or presence of 45 nM of recombinant wild type HTRA1 (HTRA1), proteolytic inactive HTRA1 
(HTRA1 S328A) or proteolytic active HTRA1 without PDZ domain (HTRA1∆PDZ). On day 14 following 
adipogenic induction, cells were stained using Oil Red O and oil droplet accrual quantified and normalized to 
cell number. *p < 0.001 as compared to untreated. Scale bar = 1 mm. Data are representative of at least 2 
separate experiments performed in triplicate. Abbreviations: hMSC, human mesenchymal stem cells; ELISA, 
enzyme-linked immunosorbent assay; HTRA1, high temperature requirement protease A1; siRNA, small 
interfering RNA.  
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Figure 2. HTRA1 interacts with surface bound HSPG. (A-F): hMSC were incubated with recombinant his-
labeled HTRA1 protein (0.45 µM) on ice for 1 h, washed and HTRA1 binding determined by FACS analysis 
using a FITC labeled anti-histidine antibody. hMSC binding of PDZ domain-containing HTRA1 S328A (A) or 
HTRA1∆protease (B) as compared to HTRA1∆PDZ. In order to investigate the involvement of HSPG in the 
binding of recombinant HTRA1 protein, cells were pre-treated with heparanase (10 U/ml) or  heparin (10 
µg/ml). hMSC binding of S328A (C, E) and HTRA1∆protease (D, F) in the presence of heparanase (C, D) or 
heparin (E, F). (G): hMSCs were induced to undergo adipogenesis in the absence (untreated) or presence 
of 45 nM of recombinant wild type HTRA1 (HTRA1), proteolytic inactive HTRA1 (HTRA1 S328A) or proteolytic 
active HTRA1 without PDZ domain (HTRA1∆PDZ). ELISA measurement of soluble syndecan-4 were 
performed at day 10 and 21 post adipogenic induction. (H): hMSCs were induced to undergo adipogenesis 
in the absence (untreated) or presence of 45 nM of recombinant wild type HTRA1 (HTRA1), proteolytic 
inactive HTRA1 (HTRA1 S328A) or proteolytic active HTRA1 without PDZ domain (HTRA1∆PDZ). At day 24 
post adipogenic induction, hMSCs were rinsed once with PBS and incubated for an additional 3 h with DiI-
labeled VLDL and carrier protein ApoE2. VLDL-DiI (red) uptake was quantified by measuring relative linear 
median fluorescence intensity (RMFI) using NIH ImageJ software and normalized to cell number. Nuclei were 
stained with DAPI (blue). Scale bar = 75 µm. *p < 0.001 as compared to untreated hMSCs. Data are 
representative of at least 2 separate experiments performed in triplicate. Abbreviations: hMSC, human 
mesenchymal stem cells; HTRA1, high temperature requirement protease A1; HSPG, heparan sulfate 
proteoglycan; ELISA, enzyme-linked immunosorbent assay; FITC, Fluorescein isothiocyanate; VLDL-DiI, 
very low density lipoprotein-dialkylcarbocyanine.  
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Figure 3. HTRA1 upregulates MMP production by hMSCs undergoing adipogenesis. hMSCs were induced to 
undergo adipogenesis in the absence (untreated) or presence of 45 nM of recombinant wild type HTRA1 
(HTRA1), proteolytic inactive HTRA1 (HTRA1 S328A) or proteolytic active HTRA1 without PDZ domain 
(HTRA1∆PDZ). At 21 days post adipogenic induction, expression levels of MMP1 (A), MMP2 (B), MMP3 (C), 
MMP9 (D), MMP13 (E), and MMP14 (F) were determined by RT-qPCR. Data was normalized to GUSB and 
expressed as fold change as compared to untreated hMSCs (value = 1) using the comparative CT method. 
(G, H): hMSCs were induced to undergo adipogenesis in the absence (untreated) or presence of 45 nM of 
recombinant wild type HTRA1 (HTRA1), proteolytic inactive HTRA1 (HTRA1 S328A) or proteolytic active 
HTRA1 without PDZ domain (HTRA1∆PDZ). At 21 days post adipogenic induction, levels of secreted MMP-3 
(G) and -13 (H) were determined in hMSC supernatants using specific ELISAs. *p < 0.05, **p < 0.001 as 
compared to untreated hMSCs. Data are representative of at least 2 separate experiments performed in 
triplicate. Abbreviations: hMSC, human mesenchymal stem cells; HTRA1, high temperature requirement 
protease A1; MMP, matrix metalloproteinase; RT-qPCR, reverse transcription-quantitative polymerase chain 
reaction; ELISA, enzyme-linked immunosorbent assay.  
60x44mm (600 x 600 DPI)  
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Figure 4. Immunofluorescence analysis of ECM. hMSCs were induced to undergo adipogenesis in the 
absence (untreated) or presence of 45 nM of recombinant wild type HTRA1 (HTRA1), proteolytic inactive 
HTRA1 (HTRA1 S328A) or proteolytic active HTRA1 without PDZ domain (HTRA1∆PDZ). At day 24 post 
adipogenic induction, hMSCs were stained with antibodies specific for laminin (A) or type IV collagen (B) 
and positive staining detected using a Cy3-labelled secondary antibody (red). Immunofluorescence was 
quantified by measuring relative linear median fluorescence intensity (RMFI) using NIH ImageJ software and 
normalized to cell number. Nuclei were stained with DAPI (blue). Scale bar = 100 µm. *p < 0.01 as 
compared to untreated hMSCs. Data is representative of at least 2 separate experiments performed in 
triplicate. Abbreviations: hMSC, human mesenchymal stem cells; HTRA1, high temperature requirement 
protease A1.  
81x81mm (600 x 600 DPI)  
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Figure 5. HTRA1’s effects are mediated through MMP activities. (A, B): hMSCs pretreated with either 
vehicle control or with 10 µM of NNGH (A) or 20 µM of CL-82198 (B) were induced to undergo adipogenesis 
in the absence (untreated) or presence of 45 nM of recombinant wild type HTRA1 (HTRA1). At day 22 post 
adipogenic induction, hMSCs were stained with an antibody against type IV collagen and positive staining 
detected using a Cy3-labelled secondary antibody. Immunofluorescence was quantified by measuring 
relative linear median fluorescence intensity (RMFI) using NIH ImageJ software and normalized to cell 
number. (C, D): hMSCs pretreated with either vehicle control or with varying concentrations of NNGH (C) or 
CL-82198 (D) were induced to undergo adipogenesis in the absence (untreated) or presence of 45 nM of 
recombinant wild type HTRA1 (HTRA1). At day 17 post adipogenic induction, soluble syndecan-4 levels were 
measured in supernatants by specific ELISA. (E, F): hMSCs pretreated with either vehicle control or with 
varying concentrations of NNGH (E) or CL-82198 (F) were induced to undergo adipogenesis in the absence 
(untreated) or presence of 45 nM of recombinant wild type HTRA1 (HTRA1). At day 18 post adipogenic 
induction, cells were stained using Oil Red O and oil droplet accrual quantified and normalized to cell 
number. *p < 0.05, **p < 0.01, ***p < 0.001 as compared to controls from untreated or HTRA1-treated 
groups respectively. Data are representative of at least 2 separate experiments performed in triplicate. 
Abbreviations: hMSC, human mesenchymal stem cells; HTRA1, high temperature requirement protease A1; 
MMP, matrix metalloproteinase; ELISA, enzyme-linked immunosorbent assay.  
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Figure 6. HTRA1’s effects are mediated through MAP kinase activities. (A): hMSCs were induced to undergo 
adipogenesis in the absence (untreated) or presence of 45 nM of recombinant wild type HTRA1 (HTRA1), 
proteolytic inactive HTRA1 (HTRA1 S328A) or proteolytic active HTRA1 without PDZ domain (HTRA1∆PDZ). 
At day 14 post adipogenic induction, protein lysates were subjected to Western blot analysis using 
antibodies specific for phosphorylated and non-phosphorylated JNK, p38 and ERK. An anti-tubulin 
monoclonal was used to confirm equal loading. (B-D):  hMSCs pretreated with either vehicle control or with 
PD98059 (10 µM), SP600125 (20 µM) or SB239063 (10 µM) were induced to undergo adipogenesis in the 
absence (untreated) or presence of 45 nM of recombinant wild type HTRA1 (HTRA1). At day 17 post 
adipogenic induction, expression levels of MMP3 (B) and MMP13 (C) were determined by RT-qPCR. Data 
was normalized to GUSB and expressed as fold change relative to untreated, control hMSCs (value = 1) 
using the comparative CT method. (D): Oil Red O staining was also performed and oil droplet accrual 
quantified and normalized to cell number.  *p < 0.05, **p < 0.01, ***p < 0.001 as compared to controls 
from untreated or HTRA1-treated groups respectively. Data are representative of at least 2 separate 
experiments performed in triplicate. Abbreviations: hMSC, human mesenchymal stem cells; HTRA1, high 
temperature requirement protease A1; MMP, matrix metalloproteinase; MAP, mitogen-activated protein; RT-
qPCR, reverse transcription-quantitative polymerase chain reaction; GUSB, Glucuronidase beta.  
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Figure 7. Identification of HTRA1 in adipose tissue. Paraffin wax sections of human visceral (omental) 
adipose tissue from insulin sensitive (IS) or insulin resistant (IR) obese patients were incubated with an 
anti-HTRA1 antibody (A, B), anti-MMP-13 antibody (C) or relevant IgG controls (D-F), and positive staining 
identified using an appropriate HRP-labeled polyclonal antibody with subsequent development using 3,3'-
diaminobenzidine (brown). Arrow heads, HTRA1 or MMP-13 present in crown-like structures. Scale bar = 
200 µm. Abbreviations: HTRA1, high temperature requirement protease A1; MMP, matrix metalloproteinase; 
HRP, horseradish peroxidase.  
78x41mm (600 x 600 DPI)  
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Supplemental Table S1. List of Gene Expression Assays used in RT-qPCR analysis. 
a 
TaqMan Expression Assay identity code according to supplier (Life Technologies, Zug, 
Switzerland). 
 
 
Supplemental Table S2. Human patient information. 
 
 
 
 
 
 
a 
Defined by the glucose infusion rate (GIR) during the steady state of  
an euglycemic hyperinsulinemic clamp as previously described [21]. 
Gene  Protein Product Assay ID 
a
 
 
HTRA1 High-Temperature Requirement Protease A1 Hs01016151_m1 
MMP1 Matrix metalloproteinase 1 / Interstitial Collagenase Hs00899658_m1 
MMP2 Matrix metalloproteinase 2 / gelatinase A Hs01548727_m1 
MMP3 Matrix metalloproteinase 3 / Stromelysin-1 Hs00968305_m1 
MMP9 Matrix metalloproteinase 9 / gelatinase B Hs00234579_m1 
MMP13 Matrix metalloproteinase 13 / Collagenase-3 Hs00233992_m1 
MMP14 Matrix metalloproteinase 14 (membrane-inserted) Hs01037003_g1 
PPARG Peroxisome proliferator-activated receptor gamma Hs01115513_m1 
FABP4 Fatty acid binding protein 4 Hs01086177_m1 
CD36 Cluster of differentiation 36 Hs01567185_m1 
ADIPOQ Adiponectin Hs00605917_m1 
GUSB Glucuronidase, beta Hs99999908_m1 
Patient  Sex Age (yrs)
 
BMI (kg/m
3
) Insulin sensitivity group 
a
 
1  F 43 40.4 Insulin sensitive  
2  F 42 49.1 Insulin resistant  
3  M 43 50.7 Insulin sensitive  
4  F 56 30.9 Insulin resistant  
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Supplementary Fig. 1. (A): hMSCs were induced to undergo adipogenesis in the presence 
of varying concentrations of recombinant wild type HTRA1 (HTRA1) ranging from 0 to 
45 nM, and its influence on oil droplet accrual determined by Oil Red O staining. *p < 
0.01 as compared hMSCs cultured in the absence of HTRA1. (B): hMSCs were incubated 
in growth medium (control), osteogenic induction medium (osteogenic) or adipogenic 
induction medium (adipogenic) for up to 14 days and endogenous HTRA1 protein levels 
measured in supernatants by specific ELISA. *p < 0.001 as compared hMSCs cultured in 
growth medium at the equivalent time points. (C): hMSCs were treated with scrambled 
siRNA (scr) or siRNAs specific for HTRA1 (H1 and H2) and induced to undergo 
adipogenesis. Endogenous levels of HTRA1 were measured in supernatants at day 3 post 
adipogenic induction using a specific ELISA. *p < 0.001 as compared to scrambled siRNA 
(scr) treated cells. (D): Schematic of recombinant human HTRA1 proteins; active HTRA1 
(∆Mac), inactive HTRA1 (HTRA1 S328A), active HTRA1 without PDZ domain 
(HTRA1∆PDZ), inactive HTRA1 without PDZ domain (HTRA1 S328A∆PDZ) and 
HTRA1 without protease domain (HTRA1∆protease). The purified recombinant histidine-
labeled human HTRA1 proteins were also visualized on a Coomassie blue-stained SDS-
PAGE gel. M, protein marker; lane 1, HTRA1; lane 2, HTRA1 S328A; lane 3, 
HTRA1∆PDZ; lane 4, HTRA1 S328A∆PDZ; lane 5, HTRA1∆protease. (E): Proteolytic 
activity of recombinant HTRA1 proteins (45 nM) towards BODIPY-FL-labeled DQ elastin 
(25 µg/ml) at 37
o
C as determined using a Multiplate reader. Abbreviations: hMSC, human 
mesenchymal stem cells; HTRA1, high temperature requirement protease A1; ELISA, 
enzyme-linked immunosorbent assay; siRNA, small interfering RNA; SDS-PAGE, sodium 
dodecyl sulfate polyacrylamide gel electrophoresis. 
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Supplementary Fig. 2. Influence of HTRA1 on adipogenic markers. hMSCs were induced 
to undergo adipogenesis in the absence (untreated) or presence of 45 nM of recombinant 
wild type HTRA1 (HTRA1), proteolytic inactive HTRA1 (HTRA1 S328A) or proteolytic 
active HTRA1 without PDZ domain (HTRA1∆PDZ). At 21 days post adipogenic 
induction, expression levels of PPARG (A), FABP4 (B), CD36 (C) and ADIPOQ (D) were 
determined by RT-qPCR. Data was normalized to GUSB and expressed as fold change as 
compared to untreated hMSCs (value = 1) using the comparative CT method. *p < 0.01 as 
compared to untreated cells. Abbreviations: hMSC, human mesenchymal stem cells; 
HTRA1, high temperature requirement protease A1; PPARG, peroxisome proliferator-
activated receptor gamma; FABP4, fatty acid binding protein 4; CD36, cluster of 
differentiation 36; GUSB, Glucuronidase beta; RT-qPCR, reverse transcription-
quantitative polymerase chain reaction. 
 
Supplementary Fig. 3. FACS analysis of recombinant HTRA1 binding to non-
differentiated hMSCs. HTRA1∆protease (0.45 µM) was incubated with hMSCs for 1 h at 
4
o
C and cell-bound HTRA1 protein detected using a FITC labeled anti-his antibody. The 
influence of pre-incubating cells with collagenase (1 mg/ml) (A), chondroitinase (10 U/ml) 
(B), CS1 (50 µM) (C) or GRGDSP (50 µM) (D) on the percentage of cell-bound 
HTRA1∆protease was calculated using FlowJo 10 software. Data are representative of 
least two individual experiments performed in duplicate. Abbreviations: hMSC, human 
mesenchymal stem cells; HTRA1, high temperature requirement protease A1; FACS, 
fluorescence activated cells sorting. 
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Supplementary Fig. 4. Capacity for HTRA1 to degrade type IV collagen. Varying 
concentrations of HTRA1 or HTRA1 S328A were incubated with DQ-type IV collagen 
(25 µg/ml) at 37
o
C and the relative fluorescence units (RFU) generated after 24 h 
determined using a Multiplate reader. Abbreviations: HTRA1, high temperature 
requirement protease A1. 
 
Supplementary Fig. 5. (A): Western blot analysis of native Fnfs in concentrated 
supernatants harvested from 14 day old undifferentiated hMSCs (control), untreated 
hMSCs undergoing adipogenesis, or hMSCs undergoing adipogenesis treated with 45 nM 
of wild type HTRA1 or proteolytic inactive HTRA1 (HTRA1 S328A) for a further 24 h. 
Protein was subjected to immunoblotting using antibody Mab 1936 specific for the 
fibronectin amino-terminal fibrin- and heparin-binding domain. Arrow head indicates the 
HTRA1-cleaved 29 kDa Fnf. (B): An equimolar ratio of human plasma-derived Fn and 
wild type HTRA1 were incubated in TBS, pH 8.5, for 16 h at 37
o
C and Fnfs purified by 
affinity chromatography and analysed on a Coomassie Blue stained 4-15% gradient SDS-
PAGE gel. Fn and HTRA1 alone were also loaded and served as controls. Arrow head 
indicates the purified 29 kDa Fnf due to HTRA1-mediated cleavage. (C-E): hMSCs were 
induced to undergo adipogenesis in the absence (untreated) or presence of 45 nM of 
recombinant wild type HTRA1 (HTRA1), purified HTRA1-digested Fn (40 µg/ml) 
(Fn+HTRA1) or TBS, pH 7.6, eluate from the affinity purification reaction using HTRA1 
alone (TBS+HTRA1). At 11 days post adipogenic induction, expression levels of MMP1 
(C), MMP3 (D) and MMP13 (E) were determined by RT-qPCR. Data was normalized to 
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GUSB and expressed as fold change as compared to untreated hMSCs (value = 1) using the 
comparative CT method. (F): hMSCs were induced to undergo adipogenesis in the absence 
(untreated) or presence of 45 nM of recombinant wild type HTRA1 (HTRA1), Fn+HTRA1 
or TBS+HTRA1. At day 14 following adipogenic induction, cells were stained using Oil 
Red O and oil droplet accrual quantified and normalized to cell number. *p < 0.05, **p < 
0.01, ***p < 0.001 as compared to untreated cells. Scale bar = 2 mm. Data are 
representative of least two individual experiments performed in triplicate. Abbreviations: 
hMSC, human mesenchymal stem cells; HTRA1, high temperature requirement protease 
A1; Fnf, fibronectin fragments; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel 
electrophoresis; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; 
GUSB, Glucuronidase beta; MMP, matrix metalloproteinase; TBS, Tris-buffered saline. 
 
Supplementary Fig. 6. (A): hMSCs pre-treated with scrambled control siRNA (scr) or 
siRNAs specific for MMP13 (M1 and M2) were induced to undergo adipogenesis in the 
absence (untreated) or presence of 45 nM wild type HTRA1 (HTRA1). At day 3 post 
adipogenic induction, MMP13 gene expression was determined by RT-qPCR. Data was 
normalized to GUSB and expressed as fold change relative to siRNA (scr) controls from 
untreated hMSCs (value = 1) using the comparative CT method. (B): hMSCs pre-treated 
with scrambled control siRNA (scr) or siRNAs specific for MMP13 (M1 and M2) were 
induced to undergo adipogenesis in the absence (untreated) or presence of 45 nM wild type 
HTRA1 (HTRA1). At day 22 post adipogenic induction, cells were stained using Oil Red 
O and oil droplet accrual quantified and normalized to cell number. (C): hMSCs were 
induced to undergo adipogenesis for 14 days and then treated for 24 h without (untreated) 
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or with CL-82198 (20 µM), HTRA1 (45 nM) or HTRA1 and CL-82198. Cell supernatants 
were harvested, concentrated and subjected to Western blot analysis using an antibody 
specific for the amino-terminal fibrin- and heparin-binding domain of fibronectin. *p < 
0.05, **p < 0.01, ***p < 0.001 as compared to siRNA (scr) controls from untreated or 
HTRA1-treated groups respectively. Data are representative of least two individual 
experiments performed in triplicate. Arrow heads indicate the 29 kDa Fnf due to HTRA1 
treatment. (D): Coomassie stained gel of total protein from supernatants to control for 
equal loading. Data are representative of least two individual experiments. Abbreviations: 
hMSC, human mesenchymal stem cells; HTRA1, high temperature requirement protease 
A1; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; GUSB, 
Glucuronidase beta; MMP, matrix metalloproteinase; siRNA, small interfering RNA; Fnf, 
fibronectin fragments. 
 
Supplementary Fig. 7. Identification of HTRA1 in adipose tissue. Paraffin wax sections 
of human visceral (omental) adipose tissue from IS or IR obese patients were incubated 
with an anti-HTRA1 antibody (A, B) or relevant IgG controls (C, D), and positive staining 
identified using an appropriate HRP-labeled polyclonal antibody with subsequent 
development using 3,3'-diaminobenzidine (brown). Asterisks, HTRA1-positive blood 
vessels. Scale bar = 200 µm. Insulin sensitivity was defined as glucose infusion rate (GIR) 
during the steady state of an euglycemic-hyperinsulinemic clamp > 70 µmol/kg/min, 
insulin resistance as GIR < 50 µmol/kg/min. Abbreviations: HTRA1, high temperature 
requirement protease A1; IS, insulin sensitive; IR, insulin resistant; HRP, horseradish 
peroxidase. 
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Supplementary Fig. 8. High power image of HTRA1 in human visceral (omental) adipose 
tissue from obese patient 4 (IR). Paraffin sections were incubated with an anti-HTRA1 
antibody and positive staining identified using an appropriate HRP-labeled polyclonal 
antibody with subsequent development using 3,3'-diaminobenzidine (brown). Scale bar = 
20 µm. Abbreviations: HTRA1, high temperature requirement protease A1; IR, insulin 
resistant; HRP, horseradish peroxidase. 
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